Publications
Detailed Information
Rimabotulinumtoxinb versus onabotulinumtoxinA in the treatment of masseter hypertrophy: A 24-week double-blind randomized split-face study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Dong Hun | - |
dc.contributor.author | Jin, Seon-Pil | - |
dc.contributor.author | Cho, Soyun | - |
dc.contributor.author | Feneran, Ashley | - |
dc.contributor.author | Youn, Choon Shik | - |
dc.contributor.author | Won, Chong Hyun | - |
dc.contributor.author | Park, Gyeong-Hun | - |
dc.contributor.author | Kim, Byung Wook | - |
dc.contributor.author | An, Jeesoo | - |
dc.contributor.author | Chang, Sung Eun | - |
dc.contributor.author | Lee, Mi Woo | - |
dc.date.accessioned | 2023-12-11T07:40:01Z | - |
dc.date.available | 2023-12-11T07:40:01Z | - |
dc.date.created | 2020-07-17 | - |
dc.date.issued | 2013-08 | - |
dc.identifier.citation | Dermatology, Vol.226 No.3, pp.227-232 | - |
dc.identifier.issn | 1018-8665 | - |
dc.identifier.uri | https://hdl.handle.net/10371/198593 | - |
dc.description.abstract | Background: Masseter hypertrophy can be ameliorated by botulinum toxin. Objective: To compare the efficacy and safety of RimabotulinumtoxinB (BTX-B) and OnabotulinumtoxinA (BTX-A) in the treatment of masseter hypertrophy. Methods: Sixteen women with bilateral masseter hypertrophy received single injections of BTX-A or BTX-B at a dose ratio of 1:50 or 1:70 in a 24-week double-blind randomized split-face study. Results: Both BTX-A and BTX-B produced significant improvements in masseter hypertrophy. The maximum volume reduction, as determined by computed tomography scanning, at week 12 was comparable between BTX-A and BTX-B at a dose ratio of 1:70 (15.6 and 14.2%, respectively). At week 24, only masseters treated with BTX-A maintained a significant volume reduction. Investigator ratings and patient satisfaction scores paralleled objective computed tomography measurements. Conclusion: Both BTX-A and BTX-B are effective in the treatment of masseter hypertrophy. BTX-B, at a dose ratio of 1:70, has a comparable efficacy but a shorter duration of action than BTX-A. Copyright (C) 2013 S. Karger AG, Basel | - |
dc.language | 영어 | - |
dc.publisher | S. Karger AG | - |
dc.title | Rimabotulinumtoxinb versus onabotulinumtoxinA in the treatment of masseter hypertrophy: A 24-week double-blind randomized split-face study | - |
dc.type | Article | - |
dc.identifier.doi | 10.1159/000349984 | - |
dc.citation.journaltitle | Dermatology | - |
dc.identifier.wosid | 000322891600007 | - |
dc.identifier.scopusid | 2-s2.0-84882382769 | - |
dc.citation.endpage | 232 | - |
dc.citation.number | 3 | - |
dc.citation.startpage | 227 | - |
dc.citation.volume | 226 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Lee, Dong Hun | - |
dc.contributor.affiliatedAuthor | Cho, Soyun | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | TOXIN TYPE-A | - |
dc.subject.keywordPlus | MUSCLE | - |
dc.subject.keywordPlus | INJECTION | - |
dc.subject.keywordPlus | LINES | - |
dc.subject.keywordAuthor | Botulinum toxin | - |
dc.subject.keywordAuthor | Masseter hypertrophy | - |
dc.subject.keywordAuthor | OnabotulinumtoxinA | - |
dc.subject.keywordAuthor | RimabotulinumtoxinB | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.